MassDevice Podcast: Medical device legend Dr. Tom Fogarty

November 11, 2010 by Brian Johnson

Dr. Thomas Fogarty, the founder of the Fogarty Institute for Innovation, discusses the investment climate for medical innovation, venture capital and explains why his passion for winemaking is actually an extension of his medical career.

MassDevice Podcast: Medical device legend Dr. Tom Fogarty

The man Stanford University once dubbed "The Mickey Mantle of medical device inventors" still has his swing, or at least his sway in the industry, judging by the reaction Dr. Thomas Fogarty received in Boston recently at a round-table discussion of medical device innovation.

Fogarty is a renowned cardiologist and serial inventor with more than 100 surgical patents to his name, including the Fogarty balloon catheter, his first and best-known contribution. In Boston, the 76-year-old could barely find time to break away from well-wishers long enough to choke down a bagel. He was repeatedly approached by those wanting to thank him for helping start a career or seeking advice on starting a business. Then there were those who just wanted to tell he's a legend in the medical technology game.

"It's not only regulation. It's inappropriate regulation, unnecessary regulation and impossible regulation. The people creating the regulations are people that are only observers. They're not combatants in the field, they've never done it."

The physician, inventor and former Stanford professor is now the head of the institute that bears his name. The Fogarty Institute for Innovation is a non-profit in Mountain View, Calif., with a mission to help train and "inspire the next generation of medical innovators."

MassDevice had the chance to sit down with Fogarty to discuss the current climate for medical innovation, 510(k) reform, venture capital and why his passion for winemaking represents an extension of his medical career.

Click here to listen to the free podcast for free, or download an MP3 of the interview by right-clicking on the link.



Blame the medical device tax and the U.S. regulatory environment for the slump in investment in early-stage medical technologies, Silicon Valley Bank's Ben Johnson tells

Halyard Health, the publicly traded, $1.6 billion spinout of Kimberly-Clark's medical device business, is slated to go live in November, soon-to-be COO Chris Lowery tells

David Green tells about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years. brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.